吸入糖皮质激素联合β受体激动剂用于急性呼吸窘迫综合征高危患者的随机临床试验
该双盲随机临床试验在美国5个学术中心纳入61例经急诊科收治的ARDS高危成人,比较雾化吸入布地奈德/福莫特罗与安慰剂每日两次、最多5天。主要终点为至第5天氧饱和度除以FIO2(S/F)的纵向变化,治疗组S/F纵向升高大于对照组(p=0.02)且独立于休克(p=0.04)。S/F分类变化改善(p=0.01),但校正休克后未达统计学显著(p=0.15)。安慰剂组更多患者进展为ARDS(7 vs 0)并需要机械通气(53% vs 21%)。作者认为早期吸入布地奈德/福莫特罗可行,结果支持进一步研究其预防ARDS的疗效。
要点
- 急诊科收治的ARDS高危成人,早期(中位首剂时间<9小时)雾化吸入布地奈德/福莫特罗每日两次、最多5天,S/F纵向升高大于安慰剂组(p=0.02)。
- S/F改善独立于休克(p=0.04);但S/F分类变化在校正休克后未达统计学显著(p=0.15)。
- 安慰剂组进展为ARDS者7例 vs 治疗组0例;需要机械通气者安慰剂组53% vs 治疗组21%。
- 对照组入组时休克患者更多(14 vs 3例),可能影响结果解读。
- 作者结论为早期吸入布地奈德/福莫特罗可行并改善氧合,支持进一步研究其预防ARDS的疗效。
适用人群与场景
- 经急诊科收治的成人ARDS高危患者,来自美国5个学术中心。
处置流程与药物剂量
- 雾化吸入布地奈德/福莫特罗,每日两次(bid),最多5天;对照组为安慰剂。
- 中位自就诊至首剂研究药物时间小于9小时。
研究设计与关键结果
- 双盲随机临床试验,美国5个学术中心,纳入61例ARDS高危成人,2013年9月3日至2015年6月9日入组。
- 主要终点至第5天S/F纵向变化:治疗组升高大于对照组(p=0.02),且独立于休克(p=0.04)。
- S/F分类变化(>20%)改善(p=0.01),但校正休克后未达统计学显著(p=0.15)。
- 安慰剂组进展为ARDS 7例 vs 治疗组0例;需要机械通气安慰剂组53% vs 治疗组21%。
- 入组时休克患者对照组14例 vs 治疗组3例。
证据类型、等级与局限
- 证据类型:双盲随机临床试验(ClinicalTrials.gov: NCT01783821)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,对ARDS高危成人早期吸入布地奈德/福莫特罗可行,并改善以S/F评估的氧合;结果支持进一步研究吸入糖皮质激素和β受体激动剂预防ARDS的疗效。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: Effective pharmacologic treatments directly targeting lung injury in patients with the acute respiratory distress syndrome are lacking. Early treatment with inhaled corticosteroids and beta agonists may reduce progression to acute respiratory distress syndrome by reducing lung inflammation and enhancing alveolar fluid clearance.
DESIGN: Double-blind, randomized clinical trial (ClinicalTrials.gov: NCT01783821). The primary outcome was longitudinal change in oxygen saturation divided by the FIO2 (S/F) through day 5. We also analyzed categorical change in S/F by greater than 20%. Other outcomes included need for mechanical ventilation and development of acute respiratory distress syndrome.
SETTING: Five academic centers in the United States.
PATIENTS: Adult patients admitted through the emergency department at risk for acute respiratory distress syndrome.
INTERVENTIONS: Aerosolized budesonide/formoterol versus placebo bid for up to 5 days.
MEASUREMENTS AND MAIN RESULTS: Sixty-one patients were enrolled from September 3, 2013, to June 9, 2015. Median time from presentation to first study drug was less than 9 hours. More patients in the control group had shock at enrollment (14 vs 3 patients). The longitudinal increase in S/F was greater in the treatment group (p = 0.02) and independent of shock (p = 0.04). Categorical change in S/F improved (p = 0.01) but not after adjustment for shock (p = 0.15). More patients in the placebo group developed acute respiratory distress syndrome (7 vs 0) and required mechanical ventilation (53% vs 21%).
CONCLUSIONS: Early treatment with inhaled budesonide/formoterol in patients at risk for acute respiratory distress syndrome is feasible and improved oxygenation as assessed by S/F. These results support further study to test the efficacy of inhaled corticosteroids and beta agonists for prevention of acute respiratory distress syndrome.
参考来源
- Festic E, Carr GE, Cartin-Ceba R, et al. Randomized Clinical Trial of a Combination of an Inhaled Corticosteroid and Beta Agonist in Patients at Risk of Developing the Acute Respiratory Distress Syndrome. Crit Care Med. 2017. PMID: 28240689. doi:10.1097/CCM.0000000000002284
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。